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1. Introduction  
Invention of microarray technology in the early 1990s revolutionized the genomic research, 
where it was exploited for global gene expression profiling through screening the
expression of thousands of genes simultaneously (Watson et al., 1998). Northern blotting 
and reverse transcription polymerase chain reaction (RT-PCR) which were the traditional
techniques for monitoring changes in mRNA levels were replaced with high density arrays,
which proved to impart comprehensive data and to be better in the course of time. 
Nowadays, microarrays are used for genotyping, large scale single nucleotide
polymorphism analysis, comparative genomic hybridizations, identification of new genes, 
establishing genetic networks and as a more routine function, gene expression profiling 
(Bednar, 2000). Providing a unique tool for the determination of gene expression at
transcriptomic level, it confers simultaneous measurement of large fractions of the genome
which can facilitates the recognition of specific gene expression patterns associated with a 
certain disease or a specific pharmaceutical. Detection of the inimitable genomic signature of 
any active compound is deemed to be another important application of microarray 
technology, upon which “intrinsic genomic impacts” of any pharmacologically active agent
can be clarified. And presumably, such toxicity predication may promise notable 
information about each individual resulting in unique patterns of gene expression that, in  
turn, exhibit individual specific responses to a particular toxic substance.
Basically, the discovery of diagnostic biomarkers has been the most promising feature of
microarrays up to now and microarray technology has shown a great potential in predicting
gene function and tracking the interactions among genetic networks too (Xiang & Chen,
2000). Microarray methodology has also been applied for analysis of proteins and 
metabolites, which are the principle controllers of gene expression, to verify the results at 
the molecular level. This in turn can extend our understanding of gene expression patterns 
and molecular pathways even though other techniques such as NMR, mass spectroscopy, 
gas and liquid chromatography can be employed for metabolite profiling. Having exploited 
such techniques, for example, the identity and quantity of different molecules can be 
determined in the CSF, urine or any other biological sample. Thus, by merging the classical
techniques with new high-density microarray, the “omics” technology has been devised and
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190 Gene Therapy - Developments and Future Perspectives 
implemented for investigation on genomics, proteomics, cytomics and metabolomics (Jares,
2006; Rosa et al., 2006). The microarray is by far one of the best tools for pursuing such 
impacts. For implementation of this technology, however, one needs to be familiar with the 
different methods used in microarray data analyses and the ways for more efficient
applications of such methods to enhance the output of a microarray screening process. Fig.1
represents schematic steps of microarray (Saei & Omidi, 2011).
Fig. 1. Schematic steps of microarray, adapted with permission from (Saei & Omidi, 2011). 
The main focus of this chapter is to provide the importance of DNA microarray technology 
in gene therapy, focusing on the application of DNA microarray technology (wet lab 
approach) and also giving simple descriptions on microarray data analysis as well as
knowledge extraction (dry lab approach). In the next sections, we discuss some important 
information on the DNA microarray gene expression profiling.  
2. DNA microarray technology
DNA microarrays consist of microscopic arrays of large sets of DNA sequences that are 
immobilized on solid substrates such as glass (slide array which are identical in dimensions
to microscope slides) used as powerful tools for identification and/or quantification of 
many specific DNA sequences. Fig. 2 shows schematic illustration of spotted genes on a
glass slide array.
For printing of arrays of the desired genes, glass slide arrays are commonly used. In
practice, prior to spotting the genes, the surface of the microarray slides are uniformly 
coated with a chemical compound which is able to interact with and immobilize nucleic
acids irreversibly and attach them onto the surface. Nucleic acids (e.g., clone library, cDNAs,
PCR products, long oligonucleotides, microRNA) are then deposited on the coated surface
using contact printing, after which the slides are further treated (using UV light or baking at
80°C) to crosslink the genes spots onto the slide surface. The printed slide arrays are 
normally stored (at room temperature and dark) until required for experimentation 
(Hobman et al., 2007). 
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191Impacts of DNA Microarray Technology in Gene Therapy 
Fig. 2. Schematic illustration of spotted genes on a glass slide array. Glass slide arrays are 
produced by the robotic spotter that spots genes (e.g., PCR products, cDNAs, clone libraries
or long oligonucleotides) onto coated glass slides. Each spot on the array represents a
particular contiguous gene fragment, i.e. 40–70 nucleotides for oligonucleotide arrays, or 
several hundred nucleotides for PCR products, adapted with permission from
(Saei & Omidi, 2011).  
In DNA arrays, each spot on the array corresponds to a particular single gene. To spot 
greater numbers of genes on the slide arrays, the genes must be miniaturized and printed 
using tiny amount of biological material. The high throughput methods of sample 
preparation tend to be restricted in the amount of biological materials and concomitant with 
miniaturization of the array there has also been a trend towards decreasing the amount of 
biological material (e.g. RNA) used in the array experiments. Such approach can make the
entire process much easier and more cost-effective. It should be also noticed that the 
fabrication of microarray screening systems are swiftly moving towards nanoarrays (Chen 
& Li, 2007), upon which some limitations of microarrays such as requirement for relatively 
large sample volumes and elongated incubation time can be resolved. We use the glass slide
arrays commercially available by the Ocimum Bioslutions (www.ocimumbio.com/) mainly 
for gene expression profiling in cancer nanomedicine studies. The spotted glass slide arrays
are now widely being used for research purposes as their fabrication is simple and cost-
effective even though the spotting of genes tend not to be a simple approach by means of a
printing machine (spotter). For printing the glass slide microarrays, the noncontact 
deposition and contact deposition methods have been widely used. The first uses ink-jet 
printing technology to deposit small droplets of liquid of pre-synthesized oligonucleotides 
or other biological materials onto a solid surface. The second uses physical deposition of
small volumes of liquid from a metal pin onto the slide surface. Both of these technologies 
exploit microfluidics/nanofluidics approaches.
Basically, nucleic acid hybridization is the keystone of the DNA microarray technology.
When denatured, single stranded nucleic acids are incubated together under certain 
conditions, hybridization can occur, upon which the formation of base paired duplex 
molecules can be prompted through G:C and/or A:T hydrogen bounds base paring. As a 
matter of fact the nucleic acids hybridization process may be influenced by the
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192 Gene Therapy - Developments and Future Perspectives 
concentration and complexity of the sample, which also can be improved through 
manipulation of time, temperature and ionic strength of the hybridization buffer (Hobman
et al., 2007). Maladjustment of these parameters may lead to some inadvertent mismatches
in the nucleic acid duplex, resulting in undesired outcomes.  Removal of mismatched 
hybrids is generally conducted under increasing stringency (i.e., by decreasing salt 
concentration and/or increasing temperature). Given that the removal of mismatched 
hybridization is difficult and may affect the end point results of the experiment, thus the
more suitable experimental design with best variable adjustment should be considered 
(Hobman et al., 2007). 
In general, some major applications and/or technologies of DNA microarrays are: 1) gene
expression profiling, 2) pathogen detection and characterization, 3) comparative genome
hybridization (CGH), 4) mutation and single nucleotide polymorphism (SNP) detection, 5) 
genotyping, 6) whole genome resequencing, 7) determining protein-DNA interactions using 
ChIP-chip (also known as ChIP-on-chip), 8) regulatory RNA studies, 9) alternative splicing
detection (exon junction array), 10) RNA binding protein analysis, 11) microRNA studies, 
and 12) methylome analysis (DNA methylation profiling).
Recently, the US Food and Drug Administration (FDA) has conducted a project named
"MicroArray Quality Control (MAQC)” upon which FDA aims to develop standards and 
quality control metrics which will eventually allow the use of microarray data in drug 
discovery, clinical practice and regulatory decision-making procedures. MAQC has gone to 
phase III now (i.e., MAQC-III, also called Sequencing Quality Control (SEQC)). The MAQC­
III aims at: 1) assessing the technical performance of next-generation sequencing platforms, 
through generating benchmark datasets with reference samples, and 2) evaluating the
advantages and limitations of various bioinformatics strategies in RNA and DNA analyses
(Shi, 2008). 
In practice, DNA microarray can be divided into two main dimensions, i.e., wet lab (Fig. 3A) 
and dry lab dimensions (Fig. 3B). The main steps of experimental approach for 
transcriptomics DNA microarray are shown in Fig. 3. Based on experiment question, the
arrays are printed (Fig. 2) or the desired format of commercially available slide arrays are 
purchased. The wet lab experiments consists of: 1) sample preparation and total RNA 
extraction, 2) RT reaction and cDNA labeling (preparation for direct or indirect labeling,
e.g., using aminoallyl tagged dUTP), 3) cyanine dyes (Cy3/Cy5) post labeling, 4) co
hybridization of labeled cDNAs (Cy3-cDNA and Cy5-cDNA), 5) washing and scanning, 6)
image acquisition, and 7) data analysis. 
3. Wet lab experiments
3.1 Experimental design and sample preparation
A key to successful implementation of the DNA microarray technology is experimental
design and quality of samples, i.e. the more accurate design, the more reliable microarray
data. The user must make precise questions/hypotheses to be addressed through recruiting 
such technology, so are the statistical implications (e.g., replications, power analysis, 
clustering, principal component analysis (PCA), etc.). It has to be clarified that whether 
comparisons made on the microarray are to be direct or indirect (by making comparisons 
within or between slides, the so called type I/II experiments), and also whether 
experimental design needs to be single or multi-factorial (Shi, 2008). 
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193Impacts of DNA Microarray Technology in Gene Therapy 
Fig. 3. Main steps of the experimental approach of transcriptomics DNA microarray for wet 
(A) and dry (B) lab experiments; adapted with permission from (Saei & Omidi, 2011). 
In sample preparation, usually total RNA is isolated from the designated sample (e.g., 
animal/plant cells). Total RNA (10-20 µg), in the case of indirect labeling, is then converted 
to cDNA using tagged dNTPs (e.g., aminoallyl dUTP ) and labeled with cyanine dyes
(Cy3/Cy5) before hybridization to the array. Fundamentally, of critical importance to any 
successful transcriptomics experiment is believed to be the quality, quantity, and integrity of
the isolated RNA (total RNA or mRNA) used in microarray experiments.  Among various
commercially available RNA isolation kits (e.g., from Sigma-Aldrich, Ambion, Qiagen, and 
Promega), we have successfully used TriReagent™ from Sigma-Aldrich Co. (Omidi et al.,
2003). It should be evoked that most of these isolation kits are designed for quick, easy and
reliable RNA extraction. Besides, in general, it is crucial to choose the best working protocol 
for RNA extraction considering vulnerability of RNA for degradation since the RNA even in 
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194 Gene Therapy - Developments and Future Perspectives 
the cell appears to show instability and short half-life to some extent. Successful use of 
commercially available kits such as RNAprotect™ (Ambion) and RNAlater™ (Qiagen) has
been also reported. In the case of total RNA use, it should be noticed that only a small 
fraction of total RNA is mRNA, thus 10-20 μg of total RNA is commonly used to obtain 
sufficient mRNA for a transcriptomics microarray experiment. However, prior to 
conducting microarray experiment, the quality and quantity of the isolated total RNA has to 
be checked - the electrophoresed total RNA much be intact, showing 28s and 18s bands 
respectively at ~5 kbp and ~2 kbp using agarose gel electrophoresis, and the UV absorbance 
ratio (both for 260/280 and 260/230) must be about 1.8-2 using UV micro­
spectrophotometers (e.g., Nanodrop™). 
3.2 Labeling and hybridization
For labeling of samples, direct and indirect labeling of cDNA are widely used methods. In 
both approaches, the total RNA or mRNA is converted into cDNA by means of RT reaction 
(using either oligo dT priming to the 3' polyadenylation site, or random hexamer/nonamer).
The main difference between these two approaches is direct or indirect incorporation of
fluorescent dyes (e.g., cyanine dyes, CyDyes™ (Cy3 or Cy5), Alexa™ dyes) into the cDNA, 
i.e. direct incorporation of dye into the cDNA by RT reaction (direct labeling method), and 
indirect incorporation of dye through amino-allyl dUTP into the cDNA (indirect labeling 
method). Although the direct incorporation method is simple and rapid, it seems there is a
bias of incorporation in this method so that the cDNA is labeled at higher efficiency by Cy3 
than by Cy5. To resolve this issue, dye swap experiments in treated and untreated samples 
can be performed, in which in the replicate experiment the control sample is labeled with 
Cy3 instead of Cy5 and vice-versa for test sample; and comparing the results and analysis of 
combined outcome. The indirect labeling method display less biased dye incorporation,
however its main disadvantage is that the protocols are more intricate and time consuming. 
In our research center (http://nano.tbzmed.ac.ir/), we follow the protocol of the supplier 
“Ocimum Biosolutions”. Briefly, after sticking the gas-tight sealing system (Gene Frame™), 
the hybridization buffer is preheated at 42°C for 10 min. The labeled cDNA is dissolved in 
an appropriate amount of hybridization buffer. The hybridization mixture is heated at 95°C 
for 3 min and subsequently cooled on ice for maximum 3 min. The appropriate volume of 
probe/hybridization solution is pipetted at one end of the frame and the polyester cover slip 
is carefully placed over the frame. The arrays are incubated at 42°C on a shaker in dark for 
16-24 h. For washing, the following washing buffers (WB) are used: WB1 (2x saline-sodium 
citrate (SSC), 0.1 % sodium dodecyl sulfate (SDS)), WB2 (1 x SSC), WB3 (0.5x SSC). All 
washing steps are performed at room temperature for 3-5 min each step. All buffers should
be filter sterilized. To dry the slide arrays, prior to scanning with a scanner, they are briefly
gently centrifuged.
4. Data mining  
A key point for translation of DNA microarray data into clinical application is data mining
which is deemed to be the most confounding part. Data Mining is all about automating the
process of searching for patterns in the data – it is an iterative process of discovery. As 
shown in Fig. 4, implementation of image processing and bioinformatics methodologies 
appears to be crucial for obtaining a sensible outcome from microarray data. 
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Fig. 4. Translation of DNA microarray data into clinical applications; adapted with
permission from (Saei & Omidi, 2011). 
Exploratory data analysis on microarray can help discover new patterns and networks in 
gene expression. The patterns that data mining discovers can have various forms including:
trends in data over time, clusters of data defined by important combinations of variables, 
and finally evolution of these clusters over time. Patterns could be derived from analyzing 
the change in expression of the genes, and new insights could be gained into the underlying 
biology. Using the data retrieved from the microarray we can determine gene function in the
cell, identify targets for new drug designation and reveal molecular networks and pathways
4.1 Image acquisition and primary analysis
Although the correct analysis and interpretation of microarray data is highly dependent
upon image acquisition and data production, surprisingly less attention is usually given to 
such crucial steps which include: 1) scanning of the image, 2) spot recognition, 3) gridding 4)
segmentation, and 5) intensity extraction. 
Fig. 5. Typical  fluorescent  images  of hybridized  cDNA microarray. A) Superimposed
fluorescent image of Cy3-cDNA and Cy5-cDNA hybridization. B) Fluorescent images of Cy3 
channel. C) Fluorescent  images of  Cy5 channel. Data are adapted with permission from
(Barar et al., 2009). 
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196 Gene Therapy - Developments and Future Perspectives 
Fig. 5 represents typical fluorescent images of hybridized cDNA microarray for 
superimposed image of Cy3- and Cy5-labeled cDNA as well as Cy3-labeled hybridized 
cDNA of untreated control cells and Cy5-labeled hybridized cDNA of treated cells.
For identification of each spot or gene on the slide, a grid has to be applied to the spots on
the slide using appropriate softwares (e.g., we generally use TECAN scanner with 
ArrayPro™ software). However, a manual proofreading needs to be performed to ensure
that all the spots on the array fall on the grid correctly (Lonardi & Luo, 2004). Once the 
gridding fulfilled, segmentation can be performed to separate the spots from the 
background and define the shape of each spot – there are always different shapes that do 
not have a constant diameter. Inside the circle is the signal we seek and outside is the 
background. Many methods are included in softwares for segmentation such as fixed circle 
segmentation (FCS), adaptive circle segmentation (ACS), adaptive shape segmentation 
(ASS) and histogram segmentation (HS). The selection of the best method largely depends 
on the quality of the produced images and personal interest and experience (Ahmed et al.,
2004). As the name indicates, the FCS treats all spots equally. When almost all of the spots
on the microarray are circular, the ACS has been proved to be the best approach, whereas 
ASS finds the shape which best fits the spot when the spots are not circular. The HS method
considers pixel intensities in and around each spot to decide whether that specific pixel  
belongs to that spot (Ahmed et al., 2004; Bengtsson & Bengtsson, 2006; Lehmussola et al.,
2006; Qin et al., 2005). After separation of the signal from the background, it comes to 
intensity extraction, after which the intensity ratios are calculated. To minimize the 
systematic errors, poor quality spots should be removed – that is any spot with intensity 
lower than the background plus two standard deviations should be excluded.
4.2 Normalization and transformation
Normalization and transformation of data is the first step after primary analysis and
includes background subtraction, normalization, ratio calculation and log transformation
(Geller et al., 2003; Quackenbush, 2002). Spotted arrays are routinely used for simultaneous
analysis of gene expression in untreated control and treated cells. The mRNA extracted from 
untreated control is labeled with cy3, whereas mRNA obtained from treated cells is labeled 
with cy5. To minimize the impact of these two dyes and for verification of results, dye
flipping appears to be a helpful strategy. 
Cy3 and Cy5 data will be normalized individually and then the expression ratio (as 
logarithmic scale) will be calculated. The advantage of reporting log2 instead of the intact
expression ratio is that in this way all the ratios fall between -1 and +1. Genes with a log2 of
+1, have an upregulation factor of 2 and genes with a log2 of -1 have a downregulation factor 
of 2. Genes which possess constant expressions in the two samples will have a log2 of 0. 
Normalization is the most important process in transformation and compensates for the 
experimental variability of the data and assumes that all of the genes on an array or a subset 
of them have an average expression ratio of 1.  In the scatter plot of cy5 versus cy3 
intensities, most of the genes usually form a cluster along a straight line. Cy5 intensity is 
usually less than that of the Cy3. This is normally seen in the scatter plots with deviations 
from the one to one ratio.The slope of the line (Cy5 vs. Cy3) in the scatter plot should be one
in the ideal case where there are no inconsistencies and/or all the variables are same for the
two samples, but this is not usually the case. Normalization is, in fact, the calculation of the 
slope which best fits the line. This is usually performed using regression techniques which
provide the slope value and helps removal of the unwanted effects, at the cost of losing 
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197Impacts of DNA Microarray Technology in Gene Therapy 
some information such as the absolute expression values. The most often applied methods 
for the normalization of the dye bias include: 1) local mean, 2) global mean, 3) LOcally
WEighed Scatter-plot Smoothing (LOWESS), and 4) bayesian analyses. We have effectively 
used the LOWESS normalization method. Fig. 6 represents a typical small array showing
LOWESS based normalization of data as scatter plot. 
Fig. 6. A typical scatter plot for small array representing normalized data using LOWESS 
method. Data represent gene expression changes induced by Oligofectamine™ 
nanoliposome used for gene (antisense) delivery in A549 cells. White and Black circles
respectively show unchanged and up-/down- regulated genes (with at least 2-fold changes). 
Data are adapted with permission from (Barar et al., 2009). 
Now the question is how can we select a specific normalization method which best fits the
structure of our data? In fact, the most simple normalization method is using housekeeping 
genes as reference points in the two chips and multiplying all the intensities by a constant 
until the expression of the controls get equal in the arrays under comparison (Quackenbush, 
2001). The global normalization (total intensity normalization) assumes that the total
amount of mRNA in a  cell is fixed and the  intensities of one chip are multiplied by a 
constant until the sum of the intensities of the genes in one chip equals the sum of the
intensities in the other. This method is still a simple approach and does not remove the
signal-dependent bias (Quackenbush, 2001). Regression techniques can be used instead of 
aforementioned methods for calculating the best-fit slope of the line (Kepler et al., 2002). If
regression techniques for normalization are applied locally, it will be known as LOWESS 
which can be used to heal the nonlinearity in the data. LOWESS appears to be a powerful 
method in the normalization of the intensity-dependent dye bias and has shown to be good 
enough in many studies (Berger et al., 2004; Quackenbush, 2001). Once data were 
normalized, the expression ratio is calculated and then the log2 transformation is applied. To
ensure about the quality of data produced, the expression of repeated genes on array as
internal controls and the coefficient variation (CV) of normalized untreated controls of 
various experiments as external control can be checked.
4.3 Selection of differentially expressed genes and significance examination 
The prime aim of a microarray analysis is to clarify the genes which have been differentially 
up or down regulated. The traditional method which was used for identifying the
differentially expressed genes was setting a fixed cutoff threshold (usually in 2-fold) to infer 
significance. Genes with intensity ratio above or below the fixed ratio were said to be down 
or up regulated (Baggerly et al., 2001). This method is called fold change method (Draghici, 
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198 Gene Therapy - Developments and Future Perspectives 
2002), but it is now believed to be inefficient due to the lack of a statistical basis. For 
example, if the condition under study changes the gene expression profile slightly, then this
method will give no differentially regulated genes and as a result the sensitivity will be 
almost zero. In contrast to the former example, if the affecting parameter level is too high to 
produce the optimal detectable effect and the threshold is set at two, many genes will be
selected as differentially regulated, the method will have low specificity and many genes
will pass our filter as false positives (Cui & Churchill, 2003; Gusnanto et al., 2007). Another 
disadvantage is that, in microarray technology genes with little expression levels have a low 
signal to noise ratio, which can be demonstrated by the funnel shape at the bottom of the
expression distribution in the scatter plot. It should be evoked that losing some data will be
inevitable.  
Another method for selecting differentially expressed genes is the unusual ratio which 
involves the selection of the genes for which the ratio of the experiment and control value is 
at certain distance that is usually taken ±2 standard deviation. In fact, the selected genes 
should have an “experiment: control” ratio of at least two standard deviations away from
the related mean value. Basically, this procedure is accomplished by applying a z 
transformation to the log ratio values (Draghici, 2002). 
4.4 Dimension reduction
A major problem in microarray analysis is the large number of dimensions. In gene
expression experiments each gene and each experiment may represent one dimension. 
Visual analysis of the microarray data in the original format does not yield much because if
a slide array (spotted with 1000 genes) is used to examine a particular disease in 10 patients, 
the resultant data will be of high dimensionality (which would be a matrix of 10 by 1000). To
make the most of the data, feature reduction or dimension reduction is used which renders
this possible by finding the minimum number of genes that can best describe data.
Dimensionality reduction algorithms can be classified into “feature selection” and “feature
extraction”. Feature selection is to select k dimensions, out of the original d dimensions, that
can best represent the original data set. Feature extraction is to find a new set of k
dimensions that are some combination of the original d dimensions. The most popular
feature extraction algorithms may be the linear projection method such as PCA for 
unsupervised learning and linear discriminant analysis (LDA) for supervised learning. The
number of dimensions after the methods are applied will be two as most analyses are
performed in two dimensions x and y. There is a possibility of losing some weak but 
important data in this way as they cannot compete with the impact of more important
features. The methods used in this section of analysis are PCA, correspondence analysis 
(CA), multi-dimensional scaling (MDS), and cluster analysis (Dugas et al., 2004; Nguyen,
2005; Shannon et al., 2003). 
Of the dimension reduction methods, PCA is now mostly used method as a tool in 
exploratory data analysis and for making predictive models. PCA involves a mathematical
procedure that transforms a number of possibly correlated variables into a smaller number 
of uncorrelated variables called principal components. The first principal component
accounts for as much of the variability in the data as possible, and each succeeding 
component accounts for as much of the remaining variability as possible. PCA ignores the
dimensions in which data do not vary much. PCA is closely related to factor analysis;
indeed, some statistical packages deliberately conflate the two techniques. 
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199Impacts of DNA Microarray Technology in Gene Therapy 
4.5 Grouping methods
After performing multiple experiments under different conditions (e.g., number of patients 
or various time points), genes that reveal similar expression intensities can be grouped 
under a subset of conditions. Likewise based on the pattern of the distinguishing genes, 
boundaries between different subtypes (e.g., for cancer) can be set (Belacel et al., 2006).
Grouping methods as “unsupervised method” or “supervised method” (the so called 
clustering and classification methods, respectively) can help identify co-expressed genes 
(Juan & Huang, 2007). 
4.5.1 Unsupervised grouping: clustering
Unlike supervised methods, no data is provided in unsupervised methods that include
hierarchical clustering, k means clustering and self-organizing maps (Au et al., 2004; 
Steinley, 2006). The efficiency of all these methods relies on whether high quality data has
been produced. 
Most clustering algorithms utilize a sort of distance metric (the distance between two
expression vectors), based on which they group similar profiles together. This means that 
genes closer to each other in space are grouped together. They use either statistical 
correlation coefficient (from -1 to +1) or the Euclidean distance (the square root of the sum of 
the squared differences between corresponding feature values). The common measures of 
dissimilarity are “Euclidean distance” and “Manhattan distance” (Leung & Cavalieri, 2003; 
Quackenbush, 2001). Fig. 7 represents a schematic illustration for Euclidean distance
clustering.  
The Euclidean distance (Ed) and Manhattan distance (Md) are given by equations (1) and (2), 
respectively: 
n 
2d = Σ (x − y ) (1)Ed i i
i=1
n 
d = Σ x − y (2)Md i i
i = 1 
Where xi and yi  are the measured expression values, respectively, for genes x and y in the 
experiment i, and n is the number of the experiments under the analysis. 
Fig. 7. Schematic illustration of Euclidean distance clustering of expressed genes (G); 
adapted from (Saei & Omidi, 2011). 
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200 Gene Therapy - Developments and Future Perspectives 
The best way is to calculate the distance between a gene and the centroid of the cluster, 
however sometimes the distance between the gene and the nearest neighbor is calculated. 
Hierarchical clustering is a tree-like representation of data, which can be applied in two 
manners, “bottom-up” or “top-down” methods (Chipman & Tibshirani, 2006). The bottom-
up method starts with each object representing one cluster of size 1 and at each following 
step, the two closest clusters are joined until all objects are in a single cluster of size n. The 
top-down method is the reverse phase of what was discussed and is usually of more interest 
when we aim to identify a few clusters (Chipman & Tibshirani, 2006). One major problem 
using the hierarchical clustering is that the number of the genes which undergo clustering
should not exceed several thousands, because the process may fail or become time
consuming since the algorithm calculates the distance between all genes. To resolve such
problem, one of the solutions is to exclude the unchanged genes, or alternatively applying
other methods such as K-means clustering which is faster than hierarchical clustering 
(Quackenbush, 2001). In fact, the K-means clustering uses the prior information about the
expected number of the clusters (k) which can be obtained from principle component 
analysis. Each gene is randomly assigned to one of the clusters and then the distance
between each gene with the centroid (average expression vector) of the clusters is calculated. 
If one gene is closer to the centroid of another cluster, it is moved to that cluster. The
centroids are recalculated after the assignment of all the genes to their nearest centroids in 
an iterative process. This process continues until there is no change in the members of the
clusters and the algorithm stops here (Steinley, 2006; Wilkin & Huang, 2008). Basically, the
hierarchal clustering represents the relation of the genes to each other even though this is 
not the case with K-means clustering. 
Self-organizing maps (SOMs) have been embedded with artificial neural networks (ANNs). 
And, based on the amount of the similarity of the expression vectors to reference, it is
possible to clarify which gene belongs to which cluster. In contrast to other clustering 
algorithms, SOMs provide maps with the most similar clusters along each other’s sides
which make it a little bit different from K-means clustering (Covell et al., 2003). 
One deficiency of the discussed algorithms is that a gene can only belong to just one cluster 
in the dataset, while a gene may be member of more than one cluster due to its different
functions in the cell. An example to this can be those proteins that are the major players of
complicated networks in the cell, e.g. second messengers of the cell transduction pathways
or epidermal growth factor receptor (EGFR) which is known to play various roles in
different cells. A fuzzy logic can be alternatively exploited to solve such problem, because it 
pursues clustering with overlapping. In fuzzy clustering, a gene may belong to different
clusters with specific membership degrees between zero and one specified to each cluster. 
The sum of the membership degrees of each gene in fuzzy clustering is one (Dembele &  
Kastner, 2003). 
As discussed above different clustering methods have different efficiencies and different 
algorithms and thus are likely to produce different results. Even two hierarchical clustering 
algorithms in two softwares are slightly different and do not completely match, thus the
results vary from algorithm to algorithm and from software to software. This means one 
gene may be  placed in different groups or clusters when applying different algorithms.  
Therefore, upon our experiences, it is recommended to apply various methods and different
parameters to the data analysis and then, based on the result decide what to do. Function 
prediction is another technique which can be applied after cluster analysis (Joshi et al.,
2004). Genes that behave similarly in response to different conditions are likely to have
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similar functions. Thus, the function of orphan genes (genes with unknown function) can be
inferred from the known function of other genes placed in the same cluster.
4.5.2 Supervised grouping: classification, class prediction using the input data 
In supervised methods the network is fed with some data for which the gene families are
known. Thus based on the previous data provided for the network, it predicts that a new 
feature -that has not been used in the training step- belongs to a specific family (Peng, 2006;
Wang et al., 2005). This is called “machine learning”. The classifier is trained using the 
expression of all genes (which have passed the t-test or ANOVA for determination of the
significance) as the input and then selects the features (genes) that contribute the most to
your condition, and then classifier is validated on a set of sample that was not used in 
feature selection in the later step. For example, if you have two cancer subtypes you can 
easily classify the two subtypes and select the genes that are differentially expressed in one
subtype and not in the other or using known genes you can classify the cancer subtypes. For 
comparison of more samples you need to find genes that are expressed differentially just in 
one subtype. To make a general model, one needs to apply cross-validation method (i.e., to 
split data into different training and prediction sets and to try the classifier) or leave-one-out
method (i.e., crossing out one of the features and screening the effect of deletion on the
dataset) to the data. 
Supervised methods are almost good at pattern recognition and dividing the samples into 
groups, but so far have not shown to be effective enough in the new samples, i.e. when it
comes to prediction they have lower efficiency. The supervised methods include neural
networks, logistic regression and linear discriminant analysis (LDA) (Liao & Chin, 2007; 
Linder et al., 2007; Shen & Tan, 2005; Tai & Pan, 2007). Nearest neighbor classifier is one of
the simplest classifiers (Shen & Hasegawa, 2008). If one has already performed a principal
component analysis or clustering, then it will be possible to determine the most probable
number of classes (as in K-means) in the data and the algorithm will work well.
For higher number of example it is better to use more advanced methods such as ANN
which use the brain neurons’ logic. In use of the classification methods, however,
overfitting or overtraining of the classifier algorithm is a major problem, which means if 
the classifier is provided with too many parameters a false model may perfectly fit the 
data (Babyak, 2004; Hawkins, 2004). When the degrees of freedom in parameter selection 
are more than the information content, the ability of the model is diminished or 
destroyed. In machine learning, the algorithm is trained using some part of the data for
which we know what the output will be. After training, the model should be able to
predict the output for the other part of data for which the output is unknown. When 
overfitting happens, the performance of the model on training examples will increase, but 
the prediction power will be lower. Contrary to this, if the network is not complex enough 
it will fail to detect the signal. This is called underfitting. But a too complex network will 
fit even the noise, leading to overfitting which can produce excessive variance in the 
outputs and instead of capturing the desired pattern or trend in the data, it will memorize 
the training data (Babyak, 2004; Hawkins, 2004). The best way to chuck out overfitting is 
to use lots of training data. We should have at least 10 observations per variable. If one is
looking at 30 variables, the model should be at least provided with 300 events. To avoid 
overfitting, it is also possible to use additional techniques such as cross-validation, weight 
decay, bayesian learning, early stopping and also model comparison (Babyak, 2004;
Braga-Neto & Dougherty, 2004; Hawkins, 2004).  
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4.6 Pathway analysis
Pathway analysis should be towards functional enrichment to establish networks between 
genes and proteins. This may provide better understanding about the dynamics of gene
expression that may grant a platform for reverse engineering of regulatory networks. 
Understanding the expression dynamics of gene networks helps us infer innate complexities
and phenomenological networks among genes. Defining the true place of the genes in cell 
networks is indeed the foundation of our understanding of programming and functioning 
of living cells. Studying the regulation patterns of genes in groups, using clustering and 
classification methods helps us understand different pathways in the cell, their functions, 
regulations and the way one component in the system affects the other one. These networks 
can act as starting points for data mining and hypothesis generation, helping us reverse 
engineer (Guo et al., 2006; Li et al., 2007; Mircean et al., 2004; Park et al., 2007). 
When the picture of gene interactions are established, the nodes with many connections in
the network are thought to be of crucial role in the cell function and can be considered as 
probable specific targets for drug delivery or even design of new drugs (e.g., in the case with 
EGFR or other Tyrosine Kinase genes). These pathways can tell us where the drugs act and 
also where our carriers induce toxicity (Dewey, 2002). They also help us predict the function 
of unknown genes and investigate their true place in the pathways, where gene expression
or metabolic changes have been produced due to mutations or changed environmental
conditions. Using these techniques, the mechanisms underlying diseases can be discovered. 
One of the methods used in pathway analysis is comparing the gene list to a pathway which 
gives a p value as a result. The scoring enrichment methods compare a list of the genes to
that of a pathway and count the hits; the greater the number of the hits, the greater the score
and the enrichment (Curtis et al., 2005).  Other hit-counting methods used by MAPP Finder
and Odds ratio are hit-counting methods which indicate the degree of enrichment (Doniger
et al., 2003). GenMAPP, an open source package that allows users to visualize microarray 
and proteomics data in the context of biological pathways (freely available at 
http://www.genmapp.org/), represents biological pathways in a special file format called
‘MAPPs’ which are independent of the gene expression data. It is used to group genes by 
any organizing principle (e.g., apoptosis pathways). The gene set enrichment analysis
(GSEA) is a novel method, which uses all the data on the microarray in the order of
expression, determining whether an a priori defined set of genes shows statistically
significant, concordant differences between two biological states (e.g. phenotypes) 
(Subramanian et al., 2005). This algorithm compares each gene, in turn, to the pathway or
class, and enrichment score is specified (Subramanian et al., 2007). The GSEA and Z score 
analysis provide p values which are easy to interpret, but it is not clear whether these values 
are biologically relevant. As for other methods described above, using different criteria Z 
scores can yield different results, because they are sensitive to gene list and pathway length 
(Curtis et al., 2005). 
In the gene ontology project (http://www.geneontology.org), the genes have been classified 
into a hierarchy, based on the similarities in functions. The Kyoto Encyclopedia of Genes
and Genomes (KEGG) (http://www.genome.kp/kegg/) provides searchable pathways
(Aoki & Kanehisa, 2005; Kanehisa, 2002). However, the major problem encountered is that
there are many genes with unknown functions or pathways, thus attempt should be done in 
discovering more pathways and connecting them with existing ones. With the future data
incorporated into the pathway analysis, there will sure be improvements in the information 
produced by the microarrays. One best approach for establishing relationships in the data is
to focus mainly on the genes on which a large amount of data is available.
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Reverse engineering of regulatory networks can be fulfilled using two methods, one of 
which is “time-series data” and second one is “steady-state data” of gene knockouts.  In the 
first approach, the magnitude of expression of a certain gene at a certain time point is a 
function of expression amount of the other genes at all previous time points. In the second 
approach, the effects of deleting a certain gene on the expression of other genes are
inspected and based on the regulation of the other genes the function of that certain gene is 
assessed. For example, if by deleting gene A, gene B is upregulated, then one can relatively
think that gene A, either directly or indirectly, suppresses the expression of gene B. 
However, these methods and in particular reverse engineering still lack full applicability,
because there is a need for more discovered sophisticated networks in the cells in order to 
identify the hidden role of different molecules in the circuitry of gene regulation (Curtis et 
al., 2005; Martin et al., 2007). 
5. Microarray gene expression profiling blunders 
Exploratory data analysis on microarray can help discover new patterns and networks in 
gene expression. Using the data retrieved from the microarray one can determine gene
function in the cell, identify targets for new drug designation and reveal molecular networks
and pathways (Lee et al., 2008). 
In recent years, many methods have been devised which have now found critical 
applications in the analysis of the microarray data. The methods used to explore deep into
the microarray data include the PCA, the singular value decomposition (SVD), the SOMs 
and the support vector machine (Nahar et al., 2007; Pandey et al., 2007; Wall et al., 2001; Xiao
et al., 2003; Zhu et al., 2009). Some of these methods such as PCA and clustering methods
are used for data reduction as the vast nature of the microarray data does not allow the 
analysis of the genes one by one and holism is also not possible (Leung & Cavalieri, 2003; 
Quackenbush, 2001). Most applicable methods are unsupervised, and do not require 
additional prior information to feed the algorithm. As our understanding and knowledge of 
the genes and their expression in different cells and tissues is increased, incorporation of the
known data will empower the microarray data analysis which can help show some real
potential of data. As the scientific demands grow, we will need more sophisticated
bioinformatics and biostatistics tools to fulfill the different needs in the analysis of the 
microarray data. Distinguishing the truly differentially regulated genes from noises or other 
genes is a real challenge in the first steps, because the filtered data is going to be used as a
basis for the next steps in data mining. Unfortunately there are more genes than conditions
and this makes the analysis of the data difficult. To render the microarray data more 
reliable, one needs to use more stringent data cutoffs such as the Bonferonni correction (not 
the two-fold cutoff) as the selection measure of the differentially regulated genes and 
reducing the number of the false positives in the data set (Bland & Altman, 1995). It should
be highlighted that obtaining microarray data appears to be easy, however the analysis of 
the data is usually tedious and time consuming (Loring, 2006), thus there should be special 
focus on the analysis of the microarray data. However, because of our poor understanding 
of cell pathways and molecular biology and also not incorporating the gene information 
when analyzing the data, we are not able to dig deep into the jam of data produced by 
microarrays. Another problem is that some sections of the analysis deal with genes one by 
one considering them as individuals, whereas others look at the data in a holistic way. After 
finding a responsible gene for a specific trait or function in the cell using microarray 
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technology, other methods (e.g., RT-PCR, gene silencing, northern blotting) can be applied 
on the specific gene to assure that all the steps in the microarray analysis have been 
performed correctly. The reverse is also true; i.e. microarray can be used to verify the other 
techniques (Hembruff et al., 2005). 
If microarray technology is to be employed in genomic impacts investigations of the gene 
delivery systems, then it should be noticed that microarrays are prone to many errors both
in the experimental handling and data analysis steps. In fact, it should be perceived that all 
we have is the mere fluorescence intensity emitted from the two dyes and the ratio of the
two intensities, steps which are vulnerable to many blunders. In different steps in a
microarray analysis, multiple errors can be produced. These include the efficiency of RNA 
isolation, amount of mRNA used, cDNA generation, amplification, selective incorporation 
of cyanine dyes (i.e., Cy3 or Cy5), the quality of the array, hybridization and washing 
condition, spatial bias on the array during hybridization, scanning procedures, random 
errors and other variations in the conditions (Pounds, 2006). Because of these variations and
errors, there exists a need for replicate experiments for normalizing the data, i.e., the more
replicates in experiment, the less variance in the data. Taking the log of ratio of the 
intensities can eliminate the possible non-linearity in the data. Instead of using the 2-fold 
increase/decrease in the ratio intensities for identifying differentially regulated genes, some 
statistically based techniques (e.g., ANOVA and maximum likelihood analysis) can be
applied (Bakewell & Wit, 2005; Churchill, 2004). It should be evoked that the result of a 
microarray experiment is largely dependent on statistical methods used and the results from 
two separate analyses do not usually concord because data analysis is a multiple step 
process, with each step being vulnerable to personal misunderstanding and bad
interpretations and also because many combinations of the analytic methods are possible
(Loring, 2006). One factor that contributes to the deterioration of the matter is that different
laboratories often use different defined approaches to their analyses. Analyzing the data
using different procedures makes the final results different. Each of these processes can be 
carried out using various methods, for example one can use hierarchical clustering, K-means 
clustering or self-organizing maps in the clustering step. As another example different
linkage methods are available for hierarchical clustering that the analyst is free to choose 
from, each of them producing slightly different outcomes.
Recently some attempts have been performed to bring these divergent processes into one 
homogenous procedure. For overcoming the problem, the Microarray Gene Expression Data 
(MGED) society (http://www.mged.org) proposed standards termed as “Minimum 
Information About a Microarray Experiment (MIAME) standards” for homogenization of 
the microarray experiments and data handling (Whetzel et al., 2006). Many journals today 
require submissions to be in compliance with MIAME, upon which many experiments are 
now in concordance with MIAME in experimental design, implementation and data 
analysis. This may provide researchers a platform to share their data, to cooperate for better 
data analysis and comparison of experiments. The six most critical elements in MIAME are: 
1) the raw data for each hybridization, 2) the final normalized data for the set of 
hybridizations, 3) the essential sample annotation including experimental factors and their 
values (e.g., compound and dose in a dose response experiment), 4) experimental design, 5) 
sufficient annotation of the array (e.g., gene identifiers, genomic coordinates, probe
sequences or reference commercial array catalog number), and 6) the essential laboratory 
and data processing protocols; reader is directed to see (http://www.mged.org/ 
Workgroups/ MIAME/miame.html) for a review of these standards. Unfortunately, the
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variations in two separate experiments can also be due to the true variation in the samples.
For optimal minimization of the errors and avoidance of irreproducible measurements in
the microarray analyses, it is often recommended to conduct the experiment in three
separate replicates. By further increasing the number of the repeats, the confidence level
increases even though it is not usually practical due to economic issues. Basically, the order 
in which the data analysis methods are applied appears to be: 1) image analysis, 2)
normalization, 3) clustering, 4) pathway analysis, 5) promoter analysis, 6) function 
prediction, and 7) classification (Allison et al., 2006; De, V et al., 2007; Olson, 2006). 
6. Gene therapy trials and microarray technology
Gene therapy appears to be one of the most challenging fields even though gene therapy 
researches have been tarnished with the death of Jesse Gelsinger in 1999 ( the first publicly
identified person to die in a gene therapy trial). However, many positive phase II/III trials 
seem to accelerate these researches. Table 1 represents the latest state of the gene therapy 
clinical trials worldwide.
Phase
Number and percentage 
of clinical trials
(1989-2010) 
Phase I 995 (60.5%)
Phase I/II 308 (18.7%)
Phase II 267 (16.2%)
Phase II/III 13 (0.8%)
Phase III 57 (3.5%)
Phase IV 2 (0.1%)
Single subject 2 (0.1%)
Total 1644 
Table 1. Gene therapy clinical trials worldwide, data are from (Edelstein, 2011).
For example, Contusugene ladenovec (Advexin™, INGN-201; Introgen Therapeutics Inc.)
has been announced as a first-generation gene therapy for cancer, targeting the cancer
suppressor gene p53. Based upon the phase III trial results showing fairly good responses of 
certain patients to Advexin™, it has been accepted to be reviewed by the European
Medicines Agency. Having observed additive/synergistic effects in a variety of tumor types 
(non-small-cell lung carcinomas, squamous cell carcinoma of the head and neck, 
hepatocellular carcinoma, glioma, breast, prostate and colorectal cancers), researchers in the 
field of gene therapy hope that these advancements will eventually help restore gene-based
treatment modalities alone and in combination with chemotherapy and radiation (Senzer & 
Nemunaitis, 2009). This is just a beginning of a “molecular big-bang”, a domain of science
which requires mechanistic investigations on early and late influences of gene-based 
modalities for their successful translation into clinical practice.
Of these gene therapy clinical trials, as shown in Table 1, about 4% have reached the final 
stage and it is expected to see several gene based medicines in clinic soon. About 64.5% and
8.7% of them respectively belong to cancer and cardiovascular gene therapies, which
highlight importance of these diseases (Edelstein, 2011). Table 2 represents the latest state of 
the gene delivery vectors used for gene therapy clinical trials worldwide.
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Gene delivery vector
Number and percentage 
of clinical trials
(1989-2010) 
Adenovirus 400 (23.8%)
Retrovirus 344 (20.5%)
Naked/Plasmid DNA 304 (17.7%)
Vaccinia virus 133 (7.9%)
Lipofection 109 (6.5%)
Poxvirus 93 (5.5%)
Adeno-associated virus 75 (4.5%)
Herpes simplex virus 56 (3.3%)
Lentivirus 29 (1.7%)
Other categories 82 (4.9%) 
Unknown 55 (3.3%)
Table 2. Gene delivery vectors used for gene therapy clinical trials worldwide, data are from
(Edelstein, 2011).
So far, DNA microarray technology has been employed for detection of unknown gene-
based biomarkers in various diseases, and also for clinical diagnosis. For example, in 2010 
Qin and Tian performed a microarray gene analysis of peripheral whole blood in normal 
adult male rats after long-term growth hormone (GH) gene therapy. They reported that 61
genes were found to be differentially (p < 0.05) expressed 24 weeks after receiving GH
gene therapy. These genes were mainly associated with angiogenesis, oncogenesis, 
apoptosis, immune networks, signaling pathways, general metabolism, type I diabetes
mellitus, carbon fixation, cell adhesion molecules, and cytokine-cytokine receptor 
interaction. The results imply that exogenous GH gene expression in normal subjects is 
likely to induce cellular changes in the metabolism, signal pathways and immunity. Based
on such screening, these researchers claimed eight genes as candidate biomarkers (Qin & 
Tian, 2010).
Since genomedicines (e.g., antisense oligo deoxy nucleotides (As-ODN), RNA 
interference) can selectively block disease-causing genes, the responsible genes of diseases 
(e.g., cancer genes) have been chosen as potential targets even though undesired
nonspecific side effects may tarnish the actual mechanism of gene therapy, blemishing 
clinical development of gene based therapeutics. Using DNA microarray technology, Cho
et al. have conducted a systematic characterization of gene expression in cells exposed to 
antisense and showed that in a sequence-specific manner, antisense targeted to protein 
kinase A RIalpha alters expression of the clusters of coordinately expressed genes at a 
specific stage of cell growth, differentiation, and activation (Cho et al., 2001). These 
researchers showed that the genes defined the proliferation-transformation signature 
were down-regulated, however those genes defined the differentiation-reverse
transformation signature were up-regulated in antisense-treated cancer cells and tumors. 
And based on such findings, they concluded that the defining As-ODNs on the basis of 
their effects on global gene expression may lead to identification of clinically relevant 
antisense therapeutics and can identify which molecular and cellular events might be 
important in complex biological processes. 
A brief search of the relevant database of scientific literatures such as Medline, Toxnet and 
BIDS clearly reveals existence of a fairly large number of investigations upon gene delivery 
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and/or targeting, while little works have been undertaken on cytogenomic impacts of such 
gene delivery vectors. It is still not totally clear what genomic impacts can be elicited by a 
particular genomedicine or even by its viral/non-viral carrier(s). Although, the gene/drug 
delivery systems are generally announced as inert materials, it seems that in many occasions
they are not compatible in a genomic level. Thus, we may even face with new terminologies
such as “functional excipients” which can inevitably impose non-specific intrinsic
cytogenomic changes in target cells/tissues (Omidi et al., 2005a). 
7. Genomic impacts of gene delivery systems  
To date, the traditional chemotherapies have become an indispensable part of the cancer 
treatment procedures which almost always requires that the patient take high doses of
multiple drugs. Thus, to avoid the inevitable occurrence of side effects, there is an emergent
need for smart targeted delivery systems that provide lower toxicity and higher specificity ­
that will also be able to reduce the required dose of the drugs. Since gene therapy (using As-
ODN, siRNA, aptamer, ribozyme, etc.) can target disease at genomic level, this approach has 
attained great attention. To deliver nucleic acids to target cells, gene carriers such as viral 
and nonviral vectors (Table 2) have been widely used to overcome systemic and subcellular 
barriers. In fact, such carriers like drug delivery systems can largely influence the
pharmacokinetic properties (i.e., absorption, distribution, metabolism, and elimination) of 
drugs which are incorporated with designated carriers. Thus, there has been an increasing 
interest in design of delivery vehicles which are capable of delivering drugs (of any origin) 
inside cancer cells that is now an issue in design of molecular Trojan horses (Kim et al., 2008; 
Portney & Ozkan, 2006; Sawant et al., 2006). 
It has been revealed that most gene delivery systems can nonspecifically induce alterations 
in the gene expression profile of the target cells (Omidi et al., 2005a); an impact which is 
either parallel with the therapeutic purpose or contrary to it or even null. From another 
viewpoint the individual effect of the carriers can be cut off into two categories (i.e., early 
and late impacts). For example, we have observed that most of the cationic gene delivery 
systems (e.g., linear and branched polyethylenimine (PEI), cationic lipids and dendrimers) 
are able to induce gene expression changes intrinsically (Hollins et al., 2007; Omidi et al.,
2005b; Omidi, 2008). The determination of the early effects of a gene delivery system 
appears to be quite easy; however investigation on the late effects in a course of time is a 
cost demanding and time consuming trial. If a genomedicine is to enter clinic, there has to 
be some investigations to prove its safety. Time-series analysis can be a predictable section 
of these  investigations.  Up to now, many attempts have  been made to  design some gene  
delivery systems (viral and non-viral vectors). Some of these vectors include monoclonal
antibodies, liposomes, metabolites, peptide hormones, cytokines, growth factors, viral and 
bacteriophage particles, nanoparticles and dendrimers. The choice of the carrier depends on 
the drug and also the cell to which the drug is going to be delivered. Almost all these 
carriers have suffered from either poor uptake and little transgene expression (non-viral
vectors), or immunogenicity (viral vectors). With little efficacy of the carrier systems, some
of them are still far from clinic and the gene therapy field needs a lot of time to reach the
magic of genomedicines for treatment of diseases. 
Viral vectors have a higher efficiency but their successful applications need more 
investigations. Expression of the recombinant viruses in the target cells is transient and can 
produce an inflammatory response in the patient. Another disadvantage of these vectors is 
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that it is not known whether the re-administration is safe due to the immunological
responses. Unfortunately the first volunteer, Jesse Gelsinger who was undergone a gene 
therapy with adenoviral vectors died due to the activated viruses in the phase I gene
therapy trial in 1999 (Ferber, 2001). By far, as shown in Table 2, adenoviruses and
retroviruses (viral vectors) and liposomes (nonviral vectors) have been the most frequently 
used viral vectors for gene therapy clinical trials. Molecular Trojans were introduced into 
the field of drug targeting, when the need for more specific drug targeting was felt. For 
brain drug delivery using molecular Trojan horses (Pardridge, 2008; Patel et al., 2009),
different technologies are used including fusion protein technology, avidin biotin 
technology and Trojan horse liposome technology. Recently, tat protein transduction 
domain (PTD) as cell penetrating peptides have been used as molecular Trojans to cross
biological barriers (Dietz & Bahr, 2004). 
In non-viral vectors, DNA condensation and packaging (using cationic lipids or polymers) 
can protect gene based therapies against degradation by nucleases. These systems can also 
be equipped with specific ligands which help the carrier find its way in the hostile
environment of the body through specific receptor-ligand interactions (Duzgunes et al., 
2003; Nie et al., 2006; Putnam et al., 2001). 
Ideally a targeted therapy should be specific, but assuming the vast variety of the proteins 
and receptors on the target cell surface, a substance may inadvertently bind to the cell 
surface receptors nonspecifically. Thus, we may witness many other interactions other than 
the desired one upon implementation of a drug or a target therapy system. A glucocorticoid, 
for example, can bind to myriad of cellular receptors and accordingly may have many 
nonspecific interactions. Hence it is not far from logic if we think that many of its
interactions are still unknown. This may guide us towards a new field of science
“nonspecific genomic/proteomic signature of chemicals” (the so called genomic impacts)
(Hollins et al., 2007). Accordingly, screening the pseudo-targets of a substance or carrier can
be of great help in choosing the best carrier for a molecule, as nonspecific signaling 
pathways can be induced by carriers alone. In this regard, implementation of microarray for 
development and approval of gene based medicines can assist us in establishing the genetic
fingerprints of such modalities. In fact, now there is a growing hope that global gene
expression profiling will replace histopathology and other traditional techniques used in 
toxicology and will become the primary tool for safety evaluation of drugs and their 
carriers. Comparison of the gene expression profiles between a healthy and mutant cell can 
be used to reveal the site of the interaction of a desired drug. Therefore, the detailed 
characterization of the genomic signature for each delivery system -both the complex and 
the vector- has to be performed in different cells, since different cells respond to stimuli in 
different ways (Omidi et al., 2005b). This clearly means that our future challenge will be
finding and establishing the genomic signature for each carrier in specific cell lines -the way 
genes feel the toxicants and react against them and finally define the safety margins for 
them. This challenge requires implementation of high throughput microarray based 
screening methodology from bench works to data mining. 
8. Final remarks
With many different attempts to translate gene therapy investigation into clinic, researchers 
in this field are still feeling the optimism that they felt years ago. In fact, although the initial
burst of excitement over gene therapy hit inevitable hurdles, it appears that still we must 
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work hard to learn more and more to provide improved treatments with minimal undesired 
side effects/impacts. For example, in cancer gene therapy, we have started learning which 
genes to choose (for suppression/stimulation), how to improve expression, and amplify 
their cancer-killing abilities by adding other approaches, such as cancer vaccines and 
chemotherapy. The entire music of life played by genes are yet to be fully understood, for
which we need to get the practical and theoretical skills to comprehend the orchestral
meaning of clusters of expressed genes in relation to a particular disease.
Now, we are just targeting a single or (at maximum) couple of biomarkers to fight a disease.
This perception has to be improved through our understanding on entire picture of genomic 
expression of a biological function/disease in relation with so many others (genes/clusters 
of networked genes) that are directly/indirectly affecting the biological end point 
phenomena. Besides, a rapid, accurate, and reliable diagnostic method is necessary for 
identification of a disease for development of a suitable therapy, which consequently can 
reduce the mortality rate and also the cost of treatment. The recently developed molecular
diagnostic assays (based on DNA-DNA or protein-DNA hybridization of clinical samples) 
appear to hopefully provide a robust platform, allowing effective diagnosis of different 
diseases with high speed, sensitivity, and specificity.
In the “functional genomics era”, challenges on determination of proper analytical methods 
seem to be smoothly being shifted towards the post-analytical challenges, for which the
microarray technology can provide a revolutionary analytical platform for concurrent
analysis of thousands of genes in a single experiment.  Such an approach confers enormous
potential in the study of biological processes in health and disease. Based on recent FDA
project on microarray (MAQC), this technology is going to become a potentially important 
tool in diagnostic applications and drug discovery too. In fact, the microarray based
investigations have provided the vital impulse for biomedical experiments including: 1) 
identification of disease-causing genes in malignancies, 2) regulatory genes in the cell cycle
mechanism, 3) investigation on genomic impacts of pharmacotherapies/gene therapies. The
final point of these studies will guide us to translate our basic genomic knowledge into more
sensible clinical practice, even for development of individual therapies, perhaps by 
identifying genes for new and unique potential drug targets and predicting drug 
responsiveness for individual patients. Given altogether, it seems we can use such 
technology for prevention strategies either to improve the health and life styles.
In the future, it is deemed that most of the investments on functional genomics will largely
dependent upon research movement beyond the microarray based exploratory stages, so
that new functional genomic pipeline demand sensible translation of a list of genes resulting 
from a microarray analysis. The real value and meaningful sense of gene expression changes
need distinctive interpretation of a change by means of biological validation. Thus, the 
numerical verification of expression levels of thousands of genes need to be discovered,
perhaps by finding biological relationships between the genes which require appropriate
online systems to reveal new biological pathways in relation with clusters of the regulatory 
biomolecules. Unfortunately such an online tool has yet to be invented and till that comes
into reality; the analysis of microarray data sets will be less rewarding. Other important 
issue seems to be the growing large size of microarray data and untapped information 
available in different data bases – the question is how we can extract the best results from 
existing data sets in relation with similar sets of data? Can we build an online network for 
such aim? It should be clarified that any set of microarray data has potential to be re­
analyzed based upon many different integrative biological/clinical concepts. 
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